Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

Author(s):

Robert Z. Orlowski, MD, PhDJonathan L. Kaufman, MD

The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.

EP: 1.Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP: 2.Clinical Insights on Next Treatment Approach Steps

Now Viewing

EP: 3.Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

EP: 4.Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

EP: 5.Overview of CAR T-cell Therapy Options in R/R MM

EP: 6.Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP: 7.Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP: 8.Clinical Insights on the Patient Presentation & Treatment Course

EP: 9.Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP: 10.Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

EP: 11.Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Video content above is prompted by the following:

What selinexor combinations & doses are you currently using in your clinical practice?
What has your experience been with selinexor based-regimens? How have the frequency of TRAEs associated with Selinexor differed with lower dosing?
What has your experience been with selinexor based-regimens? How have the frequency of TRAEs associated with Selinexor differed with lower dosing?
Please comment on any differences or similarities between your Selinexor prescribing patterns & experiences.